Clinical Trials Browser

Neoplasm Metastasis, Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

105 enrolled

Tumor-Agnostic

Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05421897 2026-01-29

RAPID

Phase 1 Active not recruiting

11 enrolled

CNS

Neoplasms, Neuroblastoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Phase 1/2 Recruiting

90 enrolled

CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2 Active not recruiting

280 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

9-ING-41 in Patients With Advanced Cancers

CAMPFIRE

I-SPY

RAPID

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

ESMART

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

GRACIE

IROCAS

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

OSCAR

MK-4280-001

Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

PIRATE

HIGH-LIGHT

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

CanStem303C

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Dose-Finding Study of E7070 in Combination With Irinotecan

VITA

Metformin in Children With Relapsed or Refractory Solid Tumors

Trybeca-1

A Phase II Study of Neoadjuvant FOLFIRINOX

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

BEV-ONCO2012

Study of Irinotecan on a Weekly Schedule in Children

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

PARAGON

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

FC-4

Molecularly Tailored Therapy for Pancreas Cancer

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment